Literature DB >> 8476576

T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages.

E H Nardin1, R S Nussenzweig.   

Abstract

Malaria remains a leading cause of human morbidity and mortality due to the inability of insecticides and chemotherapy/chemoprophylaxis to eliminate the vectors or disease caused by this protozoan parasite. In an effort to develop new methods of control, vaccines targeted to the various stages of the complex life cycle of Plasmodium have been developed. This review describes recent advances in the elucidation of cell-mediated immune mechanisms directed against sporozoites and liver stages of malaria parasites, their role in protection, and their relation to vaccine development. Recent data on the molecular basis of sporozoite-liver cell interaction are presented, and these may provide new approaches for chemoprophylaxis and immunoprophylaxis. We describe the role of the circumsporozoite protein, the major sporozoite surface antigen, in sporozoite movement and as a target of humoral immunity. The recognition of the circumsporozoite protein by human T cells is reviewed with emphasis on cytotoxic T cells and immune resistance against the exo-erythrocytic stage of the parasite. Earlier concepts regarding the polymorphisms of the circumsporozoite protein, the immunological relevance of this polymorphism, and predictions regarding vaccine development are reevaluated on the basis of recent data from different malaria endemic areas. Non-CS sporozoite antigens and liver stage antigens are discussed as potential targets for immune intervention. Recent experimental approaches such as multiple antigen peptides, recombinant live vectors, and new more potent adjuvants are considered for the development of more effective malaria vaccine formulations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8476576     DOI: 10.1146/annurev.iy.11.040193.003351

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  49 in total

1.  Structure of a malaria parasite antigenic determinant displayed on filamentous bacteriophage determined by NMR spectroscopy: implications for the structure of continuous peptide epitopes of proteins.

Authors:  M Monette; S J Opella; J Greenwood; A E Willis; R N Perham
Journal:  Protein Sci       Date:  2001-06       Impact factor: 6.725

2.  Determination of the Plasmodium vivax schizont stage proteome.

Authors:  Wanlapa Roobsoong; Sittiruk Roytrakul; Jetsumon Sattabongkot; Jianyong Li; Rachanee Udomsangpetch; Liwang Cui
Journal:  J Proteomics       Date:  2011-04-13       Impact factor: 4.044

3.  Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates.

Authors:  M B Joshi; A A Gam; R A Boykins; S Kumar; J Sacci; S L Hoffman; H L Nakhasi; R T Kenney
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.

Authors:  Ariane Rodríguez; Jaap Goudsmit; Arjen Companjen; Ratna Mintardjo; Gert Gillissen; Dennis Tax; Jeroen Sijtsma; Gerrit Jan Weverling; Lennart Holterman; David E Lanar; Menzo J E Havenga; Katarina Radosevic
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

5.  Force Spectroscopy of the Plasmodium falciparum Vaccine Candidate Circumsporozoite Protein Suggests a Mechanically Pliable Repeat Region.

Authors:  Aditya Prasad Patra; Shobhona Sharma; Sri Rama Koti Ainavarapu
Journal:  J Biol Chem       Date:  2016-12-27       Impact factor: 5.157

6.  Serum antibody immunoglobulin G of mice convalescent from Plasmodium yoelii infection inhibits growth of Plasmodium falciparum in vitro: blood stage antigens of P. falciparum involved in interspecies cross-reactive inhibition of parasite growth.

Authors:  P Ray; N Sahoo; B Singh; F A Kironde
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

7.  A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge.

Authors:  S Chatterjee; M Wery; P Sharma; V S Chauhan
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

8.  A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates.

Authors:  Joanna Kubler-Kielb; Fathy Majadly; Zuzana Biesova; Christopher P Mocca; Chunyan Guo; Ruth Nussenzweig; Victor Nussenzweig; Satish Mishra; Yimin Wu; Louis H Miller; Jerry M Keith; Teh-Yung Liu; John B Robbins; Rachel Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

9.  Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.

Authors:  Thomas J Powell; Jie Tang; Mary E Derome; Robert A Mitchell; Andrea Jacobs; Yanhong Deng; Naveen Palath; Edwin Cardenas; James G Boyd; Elizabeth Nardin
Journal:  Vaccine       Date:  2013-02-26       Impact factor: 3.641

10.  The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.

Authors:  Régine Audran; Floriana Lurati-Ruiz; Blaise Genton; Hildur E Blythman; Opokua Ofori-Anyinam; Christophe Reymond; Giampietro Corradin; François Spertini
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.